EDITAS MEDICINE, INC. Contract Liability (Deferred Revenue)
EDITAS MEDICINE, INC. (EDIT) had Contract Liability (Deferred Revenue) of $32.31 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-05
- 2026-06-30: Contract with Customer, Liability, Current $32.31M.
- 2025-12-31: Contract with Customer, Liability, Current $0.00.
- 2025-09-30: Contract with Customer, Liability, Current $0.00.
- 2025-06-30: Contract with Customer, Liability, Current $0.00.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $32.31M 10-Q · filed 2026-08-05 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-05 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-10 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-12 |
| 2025-03-31 | $2.00M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $6.22M 10-K · filed 2026-03-09 |
| 2024-09-30 | $14.68M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $14.68M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $14.68M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $8.22M 10-K · filed 2025-03-05 |
| 2023-09-30 | $8.22M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $8.22M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $8.22M 10-Q · filed 2023-05-05 |
| 2022-12-31 | $8.22M 10-K · filed 2024-02-28 |
| 2022-09-30 | $4.22M 10-Q · filed 2022-11-02 |
| 2022-03-31 | $5.82M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $11.33M 10-K · filed 2023-02-22 |
| 2021-09-30 | $22.67M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $34.00M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $32.70M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $20.94M 10-K · filed 2022-02-24 |
| 2020-09-30 | $19.87M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $40.94M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $40.64M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $23.51M 10-K · filed 2021-02-26 |
| 2019-09-30 | $46.02M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $56.04M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $23.40M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $15.71M 10-K · filed 2020-02-26 |
| 2018-09-30 | $8.72M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $7.39M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $13.32M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $13.24M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |